Eli Lilly Requests FDA Revoke EUA For Bamlanivimab 700 Mg Alone - Quick Facts

Eli Lilly and Company (LLY) has requested the FDA revoke the Emergency Use Authorization for bamlanivimab 700 mg alone. This is the final step in the company's transition to only supply bamlanivimab and etesevimab for administration together in the U.S. for the treatment of COVID-19. The company noted that the request is not due to any new safety concern.

Lilly's bamlanivimab was the first neutralizing monoclonal antibody to receive emergency use authorization from the FDA as a treatment for mild to moderate COVID-19. Lilly said all sites in the U.S. now have access to obtain doses of etesevimab for administration with bamlanivimab — which together neutralize more of the emerging COVID-19 variants in the U.S. than bamlanivimab alone.

Lilly, in collaboration with Amgen, plans to manufacture sufficient supply of bamlanivimab and etesevimab together. Lilly will submit only bamlanivimab administered with etesevimab together for authorization globally with a full transition expected by June 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration approved Boehringer Ingelheim Pharmaceuticals, Inc.'s Pradaxa (dabigatran etexilate) oral blood thinning medication for children. Pradaxa is the first FDA-approved blood thinning medication that children can take by mouth. The only other approved blood thinning medication for children is given by injection. Amazon.com Inc.'s two-day Prime Day event is happening now with more than 2 million deals on offer. The e-commerce giant's biggest shopping extravaganza of the year started June 21 at 3 a.m. EDT and runs for 48 hours, through June 22. Prime Day 2021 will feature the largest number of deals ever offered in the seven year history of the Prime Day Celebrations. New deals are being launched throughout The European Commission announced Tuesday that it has opened a formal antitrust investigation to assess whether Google has violated EU competition rules by favoring its own online display advertising technology services in the so called "ad tech" supply chain, to the detriment of competing providers...
Follow RTT